Frontlight ResearchEarly access
Follicular lymphoma trials, also abroad
189 open Follicular lymphoma trials worldwide. Travel and costs are your own unless the study pays them; ask the study team first.
The same trial often runs in several countries
Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1 randomization to tafasitamab for low-risk disease: a phase II study – NLG-FL7 has 4 sites in Norway and runs in 5 countries. If a site near you is full, another one may still take people.
See Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1 randomization to tafasitamab for low-risk disease: a phase II study – NLG-FL7 in all 5 countries